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Background
In the Western world colorectal cancer is one of the lead-
ing causes of cancer-related mortality, and the second
most common cancer in women and the third in men.
Identification of prognostic markers capable of predicting
patient response to chemotherapy is essential to determine
more personalised and efficient treatment strategies in
colorectal cancer, and may help identify novel therapeutic
targets. The aim of the study was to characterise the
expression of the E2A transcriptional regulator proteins,
E12/E47 (also known as TCF-3 or E2A) in colorectal can-
cer patient tissue samples. Primarily E12/E47 antibody
optimisation was required to allow us to subsequently
examine E12/E47 protein expression in colorectal cancer
tissue and investigate any correlation with patient outcome.
Methods
Candidate antibodies directed against the E12/E47 protein
were first evaluated by western blotting and densitometry
assays on four different types of human colon cancer cell
lines. Surgically resected colorectal tumours were obtained
from 198 patients presenting with Dukes B and C colorec-
tal cancer. Tissue microarrays were constructed from
Formalin-Fixed Paraffin-Embedded samples. Tissue micro-
arrays were then stained with varying dilutions of the can-
didate antibodies to establish a reliable and reproducible
staining protocol.
Results
In order to optimise the E12/E47 staining on tissue
samples, two different antibodies, a rabbit monoclonal
TCF-3 antibody (Cell Signaling) and a rabbit polyclonal
E2A antibody (Santa Cruz) were used. Serial dilutions of
these antibodies were made to determine the optimal
concentration of antibody to use. Using immunohisto-
chemistry, the first antibody did not detect any specific
signal while a nuclear/cytoplasmic localisation of
E12/E47 was identified in some tissue samples using the
E2A antibody. This staining was scored in line with the
Allred Immunohistochemistry Scoring system.
Conclusions
Via antibody and protocol optimisation we were able to
establish a protocol to specifically identify E12/E47 protein
in human colorectal cancer tissue microarrays. This
enables us to identify whether a correlation between
E12/E47 expression in colorectal cancer patient tissue
exists and whether it expression is linked to tumour
aggressiveness. The identification of novel colorectal can-
cer markers may be relevant for diagnosis and treatment
of cancer patients.
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